335
Views
49
CrossRef citations to date
0
Altmetric
Review

Post-traumatic epilepsy: current and emerging treatment options

, &
Pages 1469-1477 | Published online: 11 Aug 2014

Abstract

Traumatic brain injury (TBI) leads to many undesired problems and complications, including immediate and long-term seizures/epilepsy, changes in mood, behavioral, and personality problems, cognitive and motor deficits, movement disorders, and sleep problems. Clinicians involved in the treatment of patients with acute TBI need to be aware of a number of issues, including the incidence and prevalence of early seizures and post-traumatic epilepsy (PTE), comorbidities associated with seizures and anticonvulsant therapies, and factors that can contribute to their emergence. While strong scientific evidence for early seizure prevention in TBI is available for phenytoin (PHT), other antiepileptic medications, eg, levetiracetam (LEV), are also being utilized in clinical settings. The use of PHT has its drawbacks, including cognitive side effects and effects on function recovery. Rates of recovery after TBI are expected to plateau after a certain period of time. Nevertheless, some patients continue to improve while others deteriorate without any clear contributing factors. Thus, one must ask, ‘Are there any actions that can be taken to decrease the chance of post-traumatic seizures and epilepsy while minimizing potential short- and long-term effects of anticonvulsants?’ While the answer is ‘probably,’ more evidence is needed to replace PHT with LEV on a permanent basis. Some have proposed studies to address this issue, while others look toward different options, including other anticonvulsants (eg, perampanel or other AMPA antagonists), or less established treatments (eg, ketamine). In this review, we focus on a comparison of the use of PHT versus LEV in the acute TBI setting and summarize the clinical aspects of seizure prevention in humans with appropriate, but general, references to the animal literature.

Introduction

In about 6% of patients with epilepsy, seizures are thought to be the result of previous head trauma; frequently, seizures in these patients are difficult to control with standard antiepileptic drugs (AEDs).Citation1 The presence of early and late seizures has significant effect on subsequent outcomes, including medication use, quality of life, employment, and psychosocial adjustment. In these patients, the original insult is frequently identified from the history, but the severity of the injury may be difficult to judge. Based on studies conducted over the last several decades, patients who have suffered moderate or severe traumatic brain injury (TBI) are typically placed on an AED right after the initial trauma, usually phenytoin (PHT), but more recently also on levetiracetam (LEV), in order to alter the progression of epileptogenesis to late seizures and epilepsy. If seizures are not present in the first 7 days after trauma, the AED is weaned, with an expectation that seizures will not occur in the future. Since the concept of seizure and epilepsy prevention after TBI is well established, it is incumbent upon us to determine not only which factors, when present or absent in the latent period (time between trauma and late seizures), are important for initiating and completing the cascade of events that eventually lead to seizure occurrence, but also how we can modulate or abort this process so that seizures never occur. It is imperative to develop strategies that change the process of epileptogenesis while concurrently decreasing the chance of the development of unwanted comorbidities (eg, worsening of cognitive deficits related to TBI and AEDs). Finally, it is important to be mindful of the financial implications – PHT was found to be more cost effective than LEV in a setting of seizure prevention after TBI, but this gap may be disappearing with the costs becoming similar in the recent years, and this calculation did not take into account the effects of these treatments on long-term costs.Citation2

In this review focusing on the comparison between PHT and LEV, we summarize the clinical aspects of seizure prevention in humans, with appropriate but general references to animal literature, and provide brief discussion of potential new developments.

Epidemiology of early vs late post-traumatic epilepsy

The epidemiology of post-traumatic epilepsy (PTE) is well established. Early seizures are defined as seizures occurring in the first 7 days of trauma, while PTE is defined as seizures occurring after this period.Citation3 The incidence of early seizures after TBI is reported to be between 2.6% and 16.3%, with the differences being dependent mainly on study design.Citation3,Citation4 At least in univariate analysis, the presence of early seizures predisposes the development of late PTE; overall early seizures are thought of as an epiphenomenon and a result of an acute injury, with their presence not necessarily equating with the development of late PTE.Citation3,Citation4 In fact, the pathophysiologic mechanisms leading to early post-traumatic seizures are not clearly understood, and multiple factors are thought to play a role, including interruption of the blood–brain barrier, presence of hemorrhage, and injury-related excitotoxicity.Citation5Citation8

The reported incidence of late PTE is dependent, in part, on the study design. In a population-based cohort of 2,747 patients with TBI, the risk of PTE after a severe TBI was 7.1% at 1 year and 11.5% at 5 years. After moderate brain injury, the risk of PTE was 0.7% at 1 year and 1.6% at 5 years. The risk of PTE was not increased after mild head injury defined as head injury without skull fracture with either loss of consciousness or posttraumatic amnesia lasting less than 30 minutes.Citation9 In the trial of PHT versus placebo for seizure prevention after TBI, 86% of patients who developed seizures did so within 2 years of the incident trauma.Citation10,Citation11 Finally, in a large population-based study, the risk of PTE was relatively small and non-significantly elevated after mild injury (1.5 after adjusting for all other factors) and increased after moderate (2.9 times) and severe (17.0 times) TBI.Citation3 Salazar et alCitation12 reported the overall occurrence of PTE in 53% of Vietnam veterans who had suffered from various penetrating head wounds and who required neurosurgical intervention. More than 90% of PTE presented within the first 10 years of trauma; occurrence of PTE significantly correlated with multiple risk factors, including brain volume loss, the presence of metal fragment, hematoma, and residual neurological deficits.Citation12 These authors estimated the risk of developing epilepsy within the first year of penetrating head trauma to be 580 times higher than in a population not at risk. Finally, a recent cross-sectional study investigated PTE in a cohort of the veterans of the Afghanistan and Iraq conflicts to show age-adjusted prevalence of 6.1 per 1,000, with odds of developing epilepsy related to previous TBI of 18.77 (95% confidence interval [CI] 9.21–38.23) when compared with veterans who did not suffer TBI.Citation13 Thus, the picture painted by these epidemiological studies is that the more severe the injury the more likely the person with TBI is to develop PTE; that more than 80% of PTE starts within 2 years of TBI; that presence of skull fracture, penetrating injury, and neurological deficits predispose to the development of PTE; and that age at the time of injury may be a factor in the development of PTE.

Seizure and epilepsy prevention after TBI

The idea behind the use of AEDs in the immediate post-injury period is based on the desire to prevent the development of late PTE as a long-term, and at times debilitating, comorbidity, ie, finding a time window for an intervention that will stop the process of epileptogenesis.Citation7 However, it needs to be recognized that besides seizures and PTE, TBI is frequently followed by various immediate and long-term deficits.Citation7,Citation14,Citation15 These include, among others, focal neurological deficits, cognitive problems, changes in mood (eg, depression), movement disorders, sleep disorders, and behavioral problems. Some of these deficits may improve or resolve relatively quickly after the injury while some of them may worsen after initial improvement.Citation16,Citation17 Further, information on how treatment with AEDs in the acute phase influences long-term outcomes, including the development of PTE, is relatively sparse. Prophylaxis against seizures is a part of standard therapy in the acute phase of moderate or severe TBI. As per guidelines from multiple organizations, including the Brain Trauma Foundation and the American Academy of Neurology, the most commonly used prophylactic agent is PHT, which is typically administered for the first 7 days after TBI.Citation18,Citation19 But, while prophylaxis with PHT decreases the incidence of early posttraumatic seizures from 14.2% to 3.6% when compared with placebo, this treatment has not been shown to decrease the risk of late posttraumatic seizures and epilepsy.Citation1,Citation11

PHT has numerous side effects and drug interactions and exhibits complex nonlinear pharmacokinetics that necessitate therapeutic drug monitoring; its steady state concentrations are often not achievable within the first 7 days of therapy. Further, maintaining therapeutic levels of PHT is challenging in patients with TBI because the levels are affected by multiple factors frequently present in TBI patients, including decreased protein binding, variable gastrointestinal absorption, and increased drug clearance.Citation20 Further, while PHT reduces seizures, concerns have been raised that it may also adversely affect cognitive recovery, at least in some forms of brain injury. A recent study investigated the outcomes of patients treated with PHT for seizure prophylaxis after TBI compared with matched patients who, based on clinical judgment, had not received PHT prophylaxis.Citation20 While no differences were observed in the incidence of seizures between groups, patients treated with PHT showed worse outcomes, including Glasgow Outcomes Scale and modified Ranking Scale (both P<0.05). Multiple caveats to this study need to be considered, including small sample size, lack of randomization, and the choice of treatment versus no treatment based on personal preferences of the providers rather than predetermined schemes.Citation20

An alternative to PHT may be LEV, an agent recently added to the seizure-prevention armamentarium.Citation21Citation25 The availability of this AED is especially relevant for critically ill patients with TBI because of the ease of administration, low rate of adverse events, and potential for improved outcomes.Citation19,Citation20,Citation24 A recently reported small-scale, single-blinded randomized trial suggests the use of LEV rather than PHT in acute TBI may be associated with better 6-month cognitive outcomes.Citation24,Citation26 While promising, these preliminary single-blinded data are not sufficient to warrant a change in clinical practice. More studies are needed to determine its long-term impact after injury. To date, no prospective, double-blind randomized controlled trials (RCTs) have been conducted to compare the effects of LEV versus PHT on neurocognitive and seizure outcomes among individuals with moderate or severe TBI.Citation27,Citation28

Several ‘older’ AEDs have been evaluated for the treatment of early post-traumatic seizures with a goal of targeting the development of late PTE. These include PHT, valproate (VPA), and carbamazepine (CBZ).Citation18,Citation24 The available data on PHT, VPA, and CBZ were reviewed in a recent ‘practice parameter’ and are discussed here only briefly.Citation18 For PHT, evidence from pooled studies indicates a significantly lower risk of early post-traumatic seizures in patients who receive PHT for seizure prophylaxis when compared with placebo (relative risk 0.37) and no reduction in late post-traumatic seizures (relative risk 1.05). Oral (via feeding tube) CBZ, given immediately after TBI and continued for 18–24 months, was used for seizure prophylaxis in one quasi-randomized study in which outcomes were compared with a placebo group.Citation29 Patients treated with CBZ showed a significantly lower probability of early and late post-traumatic seizures, but the results of this study are confounded by the fact that patients were treated initially with intravenous PHT until they were able to receive oral CBZ. Finally, one study evaluated VPA for seizure prevention after TBI to show similar incidences of seizures in patients randomized to 1 week of PHT, 1 month of VPA, or 6 months of VPA (P=0.19) and a trend toward higher mortality with VPA (P=0.07); the effects of both AEDs on neuropsychological health were similar.Citation30,Citation31 Based on these results the use of VPA for seizure prevention cannot be recommended. Overall, this is surprising because VPA has been shown to be neuroprotective in several models of acute central nervous system injury (for review, see Chen et alCitation32). Thus, the available studies provide level 1 evidence for the short-term use of PHT for seizure prevention in the setting of acute brain injury, while the use of VPA and CBZ in this setting is questionable. Currently, there is no class I evidence that the ‘older’ AEDs should be used for long-term prevention of PTE.Citation18

The results of the previous studies put into perspective the proposed use of LEV in the setting of acute TBI. In animal studies, LEV has been shown to have several mechanisms of action, including modulation of neuropeptide Y receptors and neuronal Ca++ channels, threshold elevation for L-type Ca++ channel neuronal currents, modulation of neurotransmitter release via binding to the synaptic vesicle protein 2A (inhibition of Ca++ release from intracellular stores), and opposition of the negative modulation of gamma-aminobutyric acid (GABA)- and glycine-gated currents.Citation21,Citation33 These mechanisms of action could explain the unique antiepileptogenic activity of LEV, including neuroprotection, seizure prevention, and improved cognitive outcomes of LEV use in animal models of brain injury, and support its use for seizure prevention in moderate and severe TBI. To offer more detail, LEV has recently been shown to be neuroprotective in a rodent model of controlled cortical impact (CCI) and subarachnoid hemorrhage (effect that has not been observed with PHT); administration of LEV but not PHT improved functional outcomes.Citation34 Another rodent study showed that 20 days of LEV treatment following CCI, when compared with placebo, promoted neuronal sparing, decreased the volume of injury, and reduced release of pro-inflammatory interleukin (IL)-1β.Citation35 Finally, LEV alone or in combination with diazepam decreased seizure-related hippocampal neurodegeneration.Citation36 Next is the issue of seizure prevention – the process of epileptogenesis (transformation of normal brain tissue into one capable of spontaneously generating seizures) can be prevented or aborted by LEV.Citation37 While it is recognized that LEV is not antiepileptogenic in all animal models, recent studies have shown that LEV aborts hyperexcitability in hippocampal neurons after status epilepticus,Citation38 and that it exerts antiepileptogenic effects in spontaneously epileptic rats.Citation39,Citation40 Relevant to the discussion is the effect of LEV on cognition – rodents administered LEV beginning 1 day after CCI for 20 days showed improved motor and cognitive functions, including balance (beam walking), spatial learning and memory (maze navigation), and exploration.Citation35

In the setting of TBI, some of the issues related to the use of AEDs revolve around the potential effects of these medications on EEG. This is because a growing body of evidence supports the notion that interictal epileptiform discharges (IEDs) and/or seizures result in long-term cognitive deficits. In fact, IEDs have been shown not only to affect cognitive performance, including alertness and speed of processing, at the moment of their occurrenceCitation41,Citation42 but also to contribute to negative long-term cognitive outcomes such as decreased educational achievement.Citation41Citation43 The negative effect of IEDs on cognition may be comparable to the effects of brief seizures.Citation42 There is also evidence that AEDs such as LEV may positively affect the EEG by suppressing IEDsCitation44,Citation45 and by improving the overall background of the EEG; these effects are not observed with PHT.Citation46 In addition to IEDs, the other common EEG abnormalities observed in TBI are seizures.Citation12,Citation47,Citation48 Because of the abundance of EEG abnormalities, it can be difficult to separate the short- and long-term effects of the injury alone from the associated seizures. Animal studies indicate that brain trauma causes global, in addition to focal, abnormalities, and that these abnormalities are most pronounced in the most vulnerable areas – ie, hippocampus.Citation49 Further, animal model research has documented the relationship between TBI and seizuresCitation50Citation52 and the positive impact of seizure medication treatments on improving neurobehavioral outcomes in TBI.Citation35,Citation53 Recently, human studies have shown that seizures in patients with TBI disproportionately contribute to hippocampal atrophy,Citation54 that seizures cause increases in intracranial pressure and increased lactate/pyruvate ratio, both of which have deleterious effects on post-TBI recovery,Citation55,Citation56 and that patients with seizures related to any type of brain injury, when compared with matched patients without injury, have poorer outcomes and higher mortality.Citation57Citation60 Thus, there is little doubt that seizures and/or IEDs have a negative influence on recovery after TBI.

The next issue that requires consideration is cognitive performance. It is well recognized that most AEDs have negative effects on cognition. The archetypical AED for these effects is topiramate, which has been shown to negatively affect cognitive performance in healthy subjectsCitation61Citation64 and in patients with epilepsy.Citation65Citation68 The effects of PHT and LEV on cognition are not as pronounced and are likely different.Citation24,Citation25,Citation69Citation74 PHT has been noted to have significant long-term effects on cognition,Citation69 including negative effects on concentration, memory, visuo-motor functions and mental speed; these effects may be dose related.Citation75Citation77 Some studies have shown detrimental effects of PHT on cognitive performance when compared with other AEDs (eg, carbamazepineCitation75,Citation77,Citation78), with these negative effects improving after PHT discontinuation.Citation79 On the other hand, LEV as a member of the pyrrolidine class of drugs, may improve cognition via enhancing higher integrative mechanisms of the brain.Citation80,Citation81 In fact, LEV has been shown to improve a range of cognitive abilities, including visual short-term memory,Citation82 working memory,Citation83 motor functions,Citation83 psychomotor speed and concentration,Citation72,Citation84 and fluid intelligence.Citation85 Comparative data are scarce – while one small comparative study showed no difference in cognitive outcomes in patients with epilepsy treated with LEV versus PHT, the authors recognized the lack of power to detect such a difference (n=10; participants taking concurrently various AEDs including PHT, CBZ, and/or VPA).Citation86 To date, systematic direct comparisons in patients with epilepsy have not been performed, but some studies have indicated improvements in cognition when patients were either transitioned to or treated with LEV monotherapy.Citation44,Citation46 Similar improvements in cognitive performance of patients with epilepsy while treated with PHT have not been observed or reported. Finally, individuals with existing cognitive weaknesses (as in TBI) may benefit most from LEV and, in fact, a blinded study showed that recent memory improved most in patients with poor baseline scores.Citation87 In contrast to the relative paucity of epilepsy data, a recent study of patients with brain tumors after resection showed that the neurocognitive performance of patients treated with LEV was equal to or better than that of matched patients not treated with any AEDs and better than the performance of patients treated with PHT or VPA; in contrast to treatment with PHT, treatments with LEV or VPA were not associated with additional cognitive deficits.Citation88 Another study in an animal model of Alzheimer’s disease showed that treatment with LEV improved cognitive performance via reduction of epileptiform discharges and reversal of hippocampal remodeling, behavioral abnormalities, synaptic dysfunction, and deficits in learning and memory.Citation89 In addition to the effects described above, negative effects on EEG and cognitive performance have been observed in patients treated with PHT, especially at high doses and levels.Citation90,Citation91

Based on a single RCT, PHT has been shown to have a negative effect on cognitive outcomes in patients with TBI.Citation69 A recent study in subarachnoid hemorrhage showed that these effects may be dependent on the dose and treatment duration with PHT.Citation73 These findings have led some to question the use of PHT in the setting of TBI.Citation92 Newer AEDs, specifically LEV, may be better tolerated and have less adverse impact on the plasticity of recovery. Studies have shown that patients with various etiologies of brain injury, including TBI, experience better outcomes on a variety of measures (adverse effects, Modified Rankin Scale, Glasgow Outcomes Scale) when treated with LEV compared with PHT.Citation24,Citation25,Citation93,Citation94 To that end, one small retrospective non-randomized study in TBI evaluated cognitive performance and showed a trend toward improved outcomes among patients treated with LEV versus PHT (P=0.08).Citation25 Finally, a single-blinded RCT has shown better Glasgow Outcome Scale and modified Rankin Scale outcomes in patients with moderate or severe TBI who were treated with LEV versus PHT.Citation24

Evidence for seizures after brain injury and the effects of PHT vs LEV

The likelihood of early seizures is related to the severity of brain injury.Citation14 Further, as indicated above, there is some evidence that early seizures may translate into the development of long-term epilepsy,Citation95,Citation96 though the data from population-based studies are not entirely in support of this notion.Citation3,Citation9 The factors that lead to the establishment of the long-term epileptic state are not fully understood, but there is considerable evidence to suggest that seizures in the acute period may drive changes that will result in the development of PTE. Early use of AEDs may prevent these changes from occurring, reverse the process of early epileptogenesis related to injury, and prevent chronic epilepsy.Citation38,Citation97,Citation98

As mentioned previously, because of the short-term risk of seizures and long-term risks of epilepsy, patients with TBI are typically treated with AEDs for 7 days.Citation99Citation101 The most frequently used AED in this setting is PHT.Citation1,Citation11,Citation18 However, PHT was also found to be associated with substantial liver toxicity, hypotension, hematologic abnormalities, drug interactions, and sedation, all of which are problematic in critically ill patients.Citation24,Citation94 Finally, as indicated above, studies suggest that the use of PHT in this setting is associated with adverse cognitive effects, negative effects on post-TBI recovery,Citation24,Citation25,Citation69 and even negative effects on brain anatomy.Citation102

The incidence of acute post-TBI seizures depends on whether seizures are reported based on clinical (~2%) or continuous EEG (cEEG) (~22%) criteria.Citation24,Citation26,Citation59,Citation60,Citation103 Recently, cEEG monitoring has been used to determine the incidence of early seizures in critically ill patients. In TBI studies that included cEEG, the incidence of early seizures was found to range from 16% to 22%, with the vast majority of seizures being non-convulsive (52%–100%); approximately 95% of the identified seizures occurred within 72 hours of trauma. Further, it has been shown that the use of cEEG leads to treatment changes in more than 50% of the monitored patients.Citation104 These findings support the empiric use of AEDs and of the cEEG in the critical care setting.Citation60,Citation105Citation107 Finally, data from a recent randomized and blinded study support the notion that cEEG performed in the first 72 hours after TBI contributes to outcome prediction,Citation26 with alpha variability being the most important predictive factor.Citation108 Thus, suppressing or eliminating IEDs and seizures should result in improved cognitive performance, while knowledge of the cEEG characteristics can contribute to the overall long-term prediction of outcomes.

Patients with moderate or severe TBI admitted to neuroscience intensive care units are at increased risk for seizures due to their underlying neurological injury.Citation3,Citation9 Early-onset seizures in patients with TBI greatly increase the incidence of subsequent seizures/epilepsy and the chance of secondary harm, including increased intracranial pressure, hypoxia, physical injury, and mortality.Citation58,Citation96,Citation99 Any of these complications may adversely affect the cognitive and neurological status of patients with TBI, and worsen their clinical outcomes. Further, the presence of seizures or status epilepticus in patients with TBI, similar to other acute neurological insults such as stroke, is associated with increased mortality.Citation58,Citation60 Thus, seizure prevention is critical for the long-term outcomes of patients with brain injury, and cEEG may be a valuable biomarker of initial epileptogenicity and for long-term outcomes.

Thus, to summarize, while there is no level 1 evidence that LEV may be equivalent to or better than PHT when used for seizure prevention in patients with TBI, there is a substantial body of evidence that the use of LEV should be considered in this setting, and further investigations are needed. Finally, prophylaxis of late PTE is neither indicated nor recommended. The data from observational studies and RCTs provide no evidence to support such use of AEDs.

Future directions

Clinical post-TBI recovery occurs over periods of months and years, and so does the process of epileptogenesis. In fact, epileptogenesis may progress in spite of clinical improvements and in parallel with them. So, the goal of seizure prevention (clinical and research) should be to abort the process of epileptogenesis in addition to short-term seizure prevention, while not negatively affecting the process of post-TBI recovery. Multiple possible avenues need to be further investigated.

At least theoretical grounds exist for the use of several existing and potential AEDs for seizure and PTE prevention in TBI. The possibilities include the use of anticonvulsants that exert activity against AMPA receptors, including lamotrigine and topiramate.Citation109Citation112 In fact, in models of acute brain injury other than TBI, topiramate in the setting of therapeutic hypothermia has already been shown to be neuroprotective.Citation113 Further, talampanel and perampanel, two novel AEDs that are known AMPA antagonists, have also been shown to be antiepileptogenic; talampanel is also known to be neuroprotective.Citation112 Since another AMPA-receptor antagonist, NS1209, with a mechanism of action similar to that of perampanel (also a selective AMPA-receptor antagonist that decreases hyperexcitability by targeting glutamate activity at post-synaptic AMPA receptorsCitation110) has already been shown to be neuroprotective and effective in various animal models of epilepsy, including status epilepticus, we can probably assume all AEDs with this mechanism of action have similar properties.Citation112 Other potential developments may include lacosamide because of its relative ease of use and the availability of intravenous and oral forms that are easily exchangeable, and the fact that this AED has been shown to be potentially anti-epileptogenic in animal models of kindling.Citation114 Finally, ketamine, a N-methyl D-aspartate (NMDA) receptor antagonist, has recently gained attention as a possible treatment of refractory status epilepticus; this drug is known to decrease or prevent NMDA-receptor up-regulation and thus decrease the possibility of neurotoxicity via glutamate cascade.Citation115 This is especially important in view of a recent study that used CCI as a model of TBI to show that cortical excitability and glutamatergic signaling were altered following injury.Citation5 The results of this study suggest that specific cortical neuronal microcircuits may initiate and facilitate the spread of epileptiform activity following TBI and increased glutamatergic signaling due to loss of GABAergic control, which may provide a mechanism by which TBI can give rise to PTE.

Disclosure

The authors report no conflicts of interest in this work.

References

  • TemkinNRPreventing and treating posttraumatic seizures: the human experienceEpilepsia200950Suppl 2101319187289
  • CottonBAKaoLSKozarRHolcombJBCost-utility analysis of levetiracetam and phenytoin for posttraumatic seizure prophylaxisJ Trauma201171237537921825941
  • AnnegersJFHauserWACoanSPRoccaWAA population-based study of seizures after traumatic brain injuriesN Engl J Med1998338120249414327
  • AsikainenIKasteMSarnaSEarly and late posttraumatic seizures in traumatic brain injury rehabilitation patients: brain injury factors causing late seizures and influence of seizures on long-term outcomeEpilepsia199940558458910386527
  • CantuDWalkerKAndresenLTraumatic brain injury increases cortical glutamate network activity by compromising GABAergic controlCereb Cortex Epub201437
  • HermanSTEpilepsy after brain insult: targeting epileptogenesisNeurology2002599 Suppl 5S21S2612428028
  • PitkänenAKemppainenSNdode-EkaneXEPosttraumatic epilepsy – disease or comorbidity?Epilepsy Behav Epub2014211
  • SilversteinFSBarksJDHaganPLiuXHIvackoJSzaflarskiJCytokines and perinatal brain injuryNeurochem Int1997304–53753839106251
  • AnnegersJFGrabowJDGrooverRVLawsERJrElvebackLRKurlandLTSeizures after head trauma: a population studyNeurology1980307 Pt 16836897190235
  • HaltinerAMTemkinNRDikmenSSRisk of seizure recurrence after the first late posttraumatic seizureArch Phys Med Rehabil19977888358409344302
  • TemkinNRDikmenSSWilenskyAJKeihmJChabalSWinnHRA randomized, double-blind study of phenytoin for the prevention of post-traumatic seizuresN Engl J Med199032384975022115976
  • SalazarAMJabbariBVanceSCGrafmanJAminDDillonJDEpilepsy after penetrating head injury. I. Clinical correlates: a report of the Vietnam Head Injury StudyNeurology19853510140614143929158
  • PughMJOrmanJAJaramilloCAThe prevalence of epilepsy and association with traumatic brain injury in veterans of the Afghanistan and Iraq warsJ Head Trauma Rehabil Epub201441
  • LowensteinDHEpilepsy after head injury: an overviewEpilepsia200950Suppl 24919187288
  • WangHCChangWNChangHWFactors predictive of outcome in posttraumatic seizuresJ Trauma200864488388818404052
  • KatzDIAlexanderMPKleinRBRecovery of arm function in patients with paresis after traumatic brain injuryArch Phys Med Rehabil19987954884939596386
  • TillCColellaBVerwegenJGreenREPostrecovery cognitive decline in adults with traumatic brain injuryArch Phys Med Rehabil20088912 SupplS25S3419081438
  • ChangBSLowensteinDHQuality Standards Subcommittee of the American Academy of NeurologyPractice parameter: antiepileptic drug prophylaxis in severe traumatic brain injury: report of the Quality Standards Subcommittee of the American Academy of NeurologyNeurology2003601101612525711
  • RoweASGoodwinHBrophyGMNeurocritical Care Society Pharmacy SectionSeizure prophylaxis in neurocritical care: a review of evidence-based supportPharmacotherapy201434439640924277723
  • BhullarISJohnsonDPaulJPKerwinAJTepasJJ3rdFrykbergERMore harm than good: antiseizure prophylaxis after traumatic brain injury does not decrease seizure rates but may inhibit functional recoveryJ Trauma Acute Care Surg20147615460 discussion 60–6124368357
  • DewolfeJLSzaflarskiJPLevetiracetam use in the critical care settingFront Neurol2013412123986742
  • JonesKEPuccioAMHarshmanKJLevetiracetam versus phenytoin for seizure prophylaxis in severe traumatic brain injuryNeurosurg Focus2008254E318828701
  • MilliganTAHurwitzSBromfieldEBEfficacy and tolerability of levetiracetam versus phenytoin after supratentorial neurosurgeryNeurology200871966566918725591
  • SzaflarskiJPSanghaKSLindsellCJShutterLAProspective, randomized, single-blinded comparative trial of intravenous leveti-racetam versus phenytoin for seizure prophylaxisNeurocrit Care201012216517219898966
  • TaylorSHeinrichsRJJanzenJMEhtishamALevetiracetam is associated with improved cognitive outcome for patients with intracranial hemorrhageNeurocrit Care2011151808420890680
  • SteinbaughLALindsellCJShutterLASzaflarskiJPInitial EEG predicts outcomes in a trial of levetiracetam vs fosphenytoin for seizure preventionEpilepsy Behav201223328028422342434
  • BengeJFPhenisRABernettACruz-LaureanoDKirmaniBFNeurobehavioral effects of levetiracetam in patients with traumatic brain injuryFront Neurol2013419524348459
  • KirmaniBFMungallDLingGRole of intravenous levetiracetam in seizure prophylaxis of severe traumatic brain injury patientsFront Neurol2013417024198810
  • GlötznerFLHaubitzIMiltnerFKappGPflughauptKWSeizure prevention using carbamazepine following severe brain injuriesNeurochirurgia (Stuttg)19832636679 German [with English abstract]6410292
  • DikmenSSMachamerJEWinnHRAndersonGDTemkinNRNeuropsychological effects of valproate in traumatic brain injury: a randomized trialNeurology200054489590210690983
  • TemkinNRDikmenSSAndersonGDValproate therapy for prevention of posttraumatic seizures: a randomized trialJ Neurosurg199991459360010507380
  • ChenSWuHKlebeDHongYZhangJValproic acid: a new candidate of therapeutic application for the acute central nervous system injuriesNeurochem Res Epub2014131
  • ShettyAKProspects of levetiracetam as a neuroprotective drug against status epilepticus, traumatic brain injury, and strokeFront Neurol2013417224204362
  • WangHGaoJLassiterTFLevetiracetam is neuroprotective in murine models of closed head injury and subarachnoid hemorrhageNeurocrit Care200651717816960300
  • ZouHBrayerSWHurwitzMNiyonkuruCFowlerLEWagnerAKNeuroprotective, neuroplastic, and neurobehavioral effects of daily treatment with levetiracetam in experimental traumatic brain injuryNeurorehabil Neural Repair201327987888823812605
  • LeeDSRyuHJKimJEThe effect of levetiracetam on status epilepticus-induced neuronal death in the rat hippocampusSeizure201322536837723490457
  • LöscherWBrandtCPrevention or modification of epileptogenesis after brain insults: experimental approaches and translational researchPharmacol Rev201062466870021079040
  • MargineanuDGMatagneAKaminskiRMKlitgaardHEffects of chronic treatment with levetiracetam on hippocampal field responses after pilocarpine-induced status epilepticus in ratsBrain Res Bull200877528228518722515
  • RussoECitraroRScicchitanoFComparison of the antiepileptogenic effects of an early long-term treatment with ethosuximide or levetiracetam in a genetic animal model of absence epilepsyEpilepsia20105181560156919919665
  • YanHDJi-qunCIshiharaKNagayamaTSerikawaTSasaMSeparation of antiepileptogenic and antiseizure effects of levetiracetam in the spontaneously epileptic rat (SER)Epilepsia20054681170117716060925
  • AldenkampAArendsJThe relative influence of epileptic EEG discharges, short nonconvulsive seizures, and type of epilepsy on cognitive functionEpilepsia2004451546314692908
  • NicolaiJEbusSBiemansDPThe cognitive effects of interictal epileptiform EEG discharges and short nonconvulsive epileptic seizuresEpilepsia20125361051105922554146
  • AldenkampAEffects of epileptiform EEG discharges on cognitive functionZemanAKapurNJones-GotmanMEpilepsy and MemoryOxfordOxford University Press2012160176
  • KossoffEHLosJGBoatmanDFA pilot study transitioning children onto levetiracetam monotherapy to improve language dysfunction associated with benign rolandic epilepsyEpilepsy Behav200711451451717936689
  • StodieckSSteinhoffBJKolmseeSvan RijckevorselKEffect of levetiracetam in patients with epilepsy and interictal epileptiform dischargesSeizure200110858358711792161
  • ChoJRKooDLJooEYEffect of levetiracetam monotherapy on background EEG activity and cognition in drug-naïve epilepsy patientsClin Neurophysiol2012123588389122000706
  • BushnikTEnglanderJWrightJKolakowsky-HaynerSATraumatic brain injury with and without late posttraumatic seizures: what are the impacts in the post-acute phase: a NIDRR Traumatic Brain Injury Model Systems studyJ Head Trauma Rehabil2012276E36E4423131969
  • Kolakowsky-HaynerSAWrightJEnglanderJDuongTLadley-O’BrienSImpact of late post-traumatic seizures on physical health and functioning for individuals with brain injury within the communityBrain Inj201327557858623472705
  • HammRJDixonCEGbadeboDMCognitive deficits following traumatic brain injury produced by controlled cortical impactJ Neurotrauma19929111201619672
  • CoulterDARafiqAShumateMGongQZDeLorenzoRJLyethBGBrain injury-induced enhanced limbic epileptogenesis: anatomical and physiological parallels to an animal model of temporal lobe epilepsyEpilepsy Res199626181918985690
  • NiskanenJPAiraksinenAMSierraAMonitoring functional impairment and recovery after traumatic brain injury in rats by FMRIJ Neurotrauma201330754655623259713
  • PitkänenAImmonenRJGröhnOHKharatishviliIFrom traumatic brain injury to posttraumatic epilepsy: what animal models tell us about the process and treatment optionsEpilepsia200950Suppl 2212919187291
  • HooverRCMottaMDavisJDifferential effects of the anticonvulsant topiramate on neurobehavioral and histological outcomes following traumatic brain injury in ratsJ Neurotrauma200421550151215165359
  • VespaPMMcArthurDLXuYNonconvulsive seizures after traumatic brain injury are associated with hippocampal atrophyNeurology201075979279820805525
  • TimofeevICarpenterKLNortjeJCerebral extracellular chemistry and outcome following traumatic brain injury: a microdialysis study of 223 patientsBrain2011134Pt 248449421247930
  • VespaPMMillerCMcArthurDNonconvulsive electrographic seizures after traumatic brain injury result in a delayed, prolonged increase in intracranial pressure and metabolic crisisCrit Care Med200735122830283618074483
  • ManiRSchmittSEMazerMPuttMEGaieskiDFThe frequency and timing of epileptiform activity on continuous electroencephalogram in comatose post-cardiac arrest syndrome patients treated with therapeutic hypothermiaResuscitation201283784084722366352
  • SzaflarskiJPRackleyAYKleindorferDOIncidence of seizures in the acute phase of stroke: a population-based studyEpilepsia200849697498118248443
  • VespaPMNenovVNuwerMRContinuous EEG monitoring in the intensive care unit: early findings and clinical efficacyJ Clin Neuro-physiol1999161113
  • VespaPMNuwerMRNenovVIncreased incidence and impact of nonconvulsive and convulsive seizures after traumatic brain injury as detected by continuous electroencephalographic monitoringJ Neurosurg199991575076010541231
  • LoringDWWilliamsonDJMeadorKJWiegandFHulihanJTopiramate dose effects on cognition: a randomized double-blind studyNeurology201176213113721148119
  • MartinRKuznieckyRHoSCognitive effects of topiramate, gabapentin, and lamotrigine in healthy young adultsNeurology19995223213279932951
  • MeadorKJLoringDWVahleVJCognitive and behavioral effects of lamotrigine and topiramate in healthy volunteersNeurology200564122108211415985582
  • SalinskyMCStorzbachDSpencerDCOkenBSLandryTDodrillCBEffects of topiramate and gabapentin on cognitive abilities in healthy volunteersNeurology200564579279815753411
  • BlumDMeadorKBitonVCognitive effects of lamotrigine compared with topiramate in patients with epilepsyNeurology200667340040616894098
  • LeeSSziklasVAndermannFThe effects of adjunctive topiramate on cognitive function in patients with epilepsyEpilepsia200344333934712614389
  • MulaMTrimbleMRThompsonPSanderJWTopiramate and word-finding difficulties in patients with epilepsyNeurology20036071104110712682314
  • SzaflarskiJPAllendorferJBTopiramate and its effect on fMRI of language in patients with right or left temporal lobe epilepsyEpilepsy Behav2012241748022481042
  • DikmenSSTemkinNRMillerBMachamerJWinnHRNeurobehavioral effects of phenytoin prophylaxis of posttraumatic seizuresJAMA199126510127112771995974
  • GallassiRMorrealeALorussoSProcacciantiGLugaresiEBaruzziACarbamazepine and phenytoin. Comparison of cognitive effects in epileptic patients during monotherapy and withdrawalArch Neurol19884588928943395263
  • GomerBWagnerKFringsLThe influence of antiepileptic drugs on cognition: a comparison of levetiracetam with topiramateEpilepsy Behav200710348649417409025
  • HelmstaedterCWittJAThe effects of levetiracetam on cognition: a non-interventional surveillance studyEpilepsy Behav200813464264918707022
  • NaidechAMKreiterKTJanjuaNPhenytoin exposure is associated with functional and cognitive disability after subarachnoid hemorrhageStroke200536358358715662039
  • TrimbleMRCognitive hazards of seizure disordersEpilepsia198829Suppl 1S19S243292233
  • AndrewesDGBullenJGTomlinsonLElwesRDReynoldsEHA comparative study of the cognitive effects of phenytoin and carbamazepine in new referrals with epilepsyEpilepsia19862721281343956451
  • GillhamRAWilliamsNWiedmannKDButlerELarkinJGBrodieMJCognitive function in adult epileptic patients established on anticonvulsant monotherapyEpilepsy Res1990732192252289480
  • PulliainenVJokelainenMComparing the cognitive effects of phenytoin and carbamazepine in long-term monotherapy: a two-year follow-upEpilepsia19953612119512027489696
  • AldenkampAPAlphertsWCDiepmanLvan ‘t SlotBOverwegJVermeulenJCognitive side-effects of phenytoin compared with carbamazepine in patients with localization-related epilepsyEpilepsy Res199419137437813412
  • DuncanJSShorvonSDTrimbleMREffects of removal of phenytoin, carbamazepine, and valproate on cognitive functionEpilepsia19903155845912119303
  • GiurgeaCThe “nootropic” approach to the pharmacology of the integrative activity of the brainCond Reflex1973821081154736348
  • GiurgeaCEGreindlMGPreatSNootropic drugs and agingActa Psychiatr Belg19838343493586660010
  • CiesielskiASSamsonSSteinhoffBJNeuropsychological and psychiatric impact of add-on titration of pregabalin versus levetiracetam: a comparative short-term studyEpilepsy Behav20069342443116949344
  • López-GóngoraMMartínez-DomeñoAGarciaCEscartínAEffect of levetiracetam on cognitive functions and quality of life: a one-year follow-up studyEpileptic Disord200810429730519017572
  • HelmstaedterCFritzNEKockelmannEKosanetzkyNElgerCEPositive and negative psychotropic effects of levetiracetamEpilepsy Behav200813353554118583196
  • EddyCMRickardsHECavannaAEThe cognitive impact of anti-epileptic drugsTher Adv Neurol Disord20114638540722164192
  • NeyensLGAlphertsWCAldenkampAPCognitive effects of a new pyrrolidine derivative (levetiracetam) in patients with epilepsyProg Neuropsychopharmacol Biol Psychiatry19951934114197624492
  • HuangCWPaiMCTsaiJJComparative cognitive effects of levetiracetam and topiramate in intractable epilepsyPsychiatry Clin Neurosci200862554855318950374
  • de GrootMDouwLSizooEMLevetiracetam improves verbal memory in high-grade glioma patientsNeuro-oncology201315221622323233537
  • SanchezPEZhuLVerretLLevetiracetam suppresses neuronal network dysfunction and reverses synaptic and cognitive deficits in an Alzheimer’s disease modelProc Natl Acad Sci U S A201210942E2895E290322869752
  • MeadorKJLoringDWAbneyOLEffects of carbamazepine and phenytoin on EEG and memory in healthy adultsEpilepsia19933411531578422849
  • OsorioIBurnstineTHRemlerBManon-EspaillatRReedRCPhenytoin-induced seizures: a paradoxical effect at toxic concentrations in epileptic patientsEpilepsia19893022302342924747
  • FountainNShould levetiracetam replace phenytoin for seizure prophylaxis after neurosurgery?Epilepsy Curr200993717219471614
  • MilliganTAHurwitzSBromfieldEBEfficacy and tolerability of levetiracetam versus phenytoin after supratentorial neurosurgeryNeurology200871966566918725591
  • SzaflarskiJPMecklerJMSzaflarskiMShutterLAPriviteraMDYatesSLLevetiracetam use in critically ill patientsNeurocrit Care20077214014717607530
  • KilpatrickCJDavisSMHopperJLRossiterSCEarly seizures after acute stroke. Risk of late seizuresArch Neurol19924955095111580813
  • SoELAnnegersJFHauserWAO’BrienPCWhisnantJPPopulation-based study of seizure disorders after cerebral infarctionNeurology19964623503558614493
  • KlitgaardHPitkänenAAntiepileptogenesis, neuroprotection, and disease modification in the treatment of epilepsy: focus on levetiracetamEpileptic Disord20035Suppl 1S9S1612915336
  • PitkänenABolkvadzeTImmonenRAnti-epileptogenesis in rodent post-traumatic epilepsy modelsNeurosci Lett2011497316317121402123
  • DichterMAEmerging concepts in the pathogenesis of epilepsy and epileptogenesisArch Neurol200966444344719364928
  • HermanSTClinical trials for prevention of epileptogenesisEpilepsy Res2006681353816377141
  • ManiRPollardJDichterMAHuman clinical trails in antiepileptogenesisNeurosci Lett2011497325125621439351
  • SpechtUMayTSchulzRCerebellar atrophy and prognosis after temporal lobe resectionJ Neurol Neurosurg Psychiatry19976255015069153610
  • InabaKMenakerJBrancoBCA prospective multicenter comparison of levetiracetam versus phenytoin for early posttraumatic seizure prophylaxisJ Trauma Acute Care Surg201374376677323425733
  • KilbrideRDCostelloDJChiappaKHHow seizure detection by continuous electroencephalographic monitoring affects the prescribing of antiepileptic medicationsArch Neurol200966672372819506131
  • DeLorenzoRJWaterhouseEJTowneARPersistent nonconvulsive status epilepticus after the control of convulsive status epilepticusEpilepsia19983988338409701373
  • PriviteraMHoffmanMMooreJLJesterDEEG detection of nontonic-clonic status epilepticus in patients with altered consciousnessEpilepsy Res19941821551667957038
  • VarelasPNMirskiMAManagement of seizures in critically ill patientsCurr Neurol Neurosci Rep20044648949615509452
  • VespaPMBoscardinWJHovdaDAEarly and persistent impaired percent alpha variability on continuous electroencephalography monitoring as predictive of poor outcome after traumatic brain injuryJ Neurosurg2002971849212134937
  • LeeCYFuWMChenCCSuMJLiouHHLamotrigine inhibits postsynaptic AMPA receptor and glutamate release in the dentate gyrusEpilepsia200849588889718248444
  • RogawskiMARevisiting AMPA receptors as an antiepileptic drug targetEpilepsy Curr2011112566321686307
  • RussoEConstantiAFerreriGCitraroRDe SarroGNifedipine affects the anticonvulsant activity of topiramate in various animal models of epilepsyNeuropharmacology200446686587815033346
  • RussoEGittoRCitraroRChimirriADe SarroGNew AMPA antagonists in epilepsyExpert Opin Investig Drugs201221913711389
  • LiuYBarksJDXuGSilversteinFSTopiramate extends the therapeutic window for hypothermia-mediated neuroprotection after stroke in neonatal ratsStroke20043561460146515105511
  • BrandtCHeileAPotschkaHStoehrTLöscherWEffects of the novel antiepileptic drug lacosamide on the development of amygdala kindling in ratsEpilepsia200647111803180917116018
  • GaspardNForemanBJuddLMIntravenous ketamine for the treatment of refractory status epilepticus: a retrospective multicenter studyEpilepsia20135481498150323758557